DESKETO ® Dexketoprofen

DESKETO ® is a drug based on deexketoprofen salt of trometamol

THERAPEUTIC GROUP: Non-steroidal anti-inflammatory and antirheumatic drugs

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications DESKETO ® Dexketoprofen

DESKETO ® is used in the modest symptomatic treatment of pain associated with musculoskeletal, dental and gynecological inflammatory states.

Mechanism of action DESKETO ® Dexketoprofen

The dexketoprofen trometamol, salt of the active ingredient dexketoprofen, is the main constituent of DESKETO ®, a non-steroidal anti-inflammatory drug, commonly used in the treatment of pain diseases on an inflammatory basis of low clinical relevance.

The therapeutic action exerted by this active principle is essentially due to the ability to interfere in the development of inflammatory processes, modulating the expression of factors involved in the genesis and maintenance of the inflammatory process.

More precisely, this active principle is able to inhibit a series of enzymes, known as cyclooxygenases, expressed by cells subjected to traumas of various kinds, and necessary to convert some membrane phospholipids such as arachidonic acid into chemical mediators endowed with pro- inflammatory and painful such as prostaglandins and prostacyclins.

The anti-inflammatory action is also strengthened by the increased synthesis of lipoxins, mediators able to reduce chemotaxis and adhesion of the immune cells, due to the rebalancing of the metabolism of arachidonic acid.

The above molecular mechanisms translate macroscopically into the reduction of classic signs of inflammation such as pain, fever, redness and edema.

Studies carried out and clinical efficacy

1.DEXKETOPROPHEN AND VERTEBRAL SURGERY

J Neurosurg Anesthesiol. 2011 Jul; 23 (3): 193-7.

A study that demonstrates that taking dexketoprofen following a vertebral surgery operation can significantly reduce post-operative pain, guaranteeing, among other things, easier and faster healing.

2. DEXKETOPROPHENES AND SONNOLENCE

Dtsch Med Wochenschr. 1999 Oct 15; 124 (41): 1206.

Characteristic somnolence after dexketoprofen, a new analgesic].

Krappweis J, Kirch W.

Study that shows, among the side effects related to the use of dexketoprofen, also the presence of drowsiness. Although this reaction is fortunately clinically not relevant, it can be highly relevant for patients using dangerous vehicles or machinery.

3. DEXKETOPROFENE: PAINKILLER

Expert Rev Neurother. 2008 Nov; 8 (11): 1625-40.

Very interesting review that demonstrates the great efficacy and the relative safety of dexketoprofen as a pain reliever. Among the most important features to note there is certainly the enormous versatility, which makes this active principle a real pain-killer.

Method of use and dosage

DESKETO ®

25 mg tablets of dexketoprofen:

We recommend taking 50 mg of dexketoprofen every day, divided into 12.5-gram intakes every 6 hours or 25 mg every 8 -12 hours.

Generally the aforesaid dosage is sufficient to guarantee a prompt regression of the pain symptomatology, although in the most serious cases the dose could be increased up to a maximum of 75 mg daily.

An adjustment of the dosage is instead necessary in elderly patients or those suffering from renal and liver diseases.

Warnings DESKETO ® Dexketoprofen

It would be preferable to consult your doctor before taking DESKETO ®.

Instead, medical supervision becomes necessary for all those patients suffering from renal, hepatic, gastro-intestinal and cardiovascular diseases, in which the incidence and clinical severity of the possible side effects of anti-inflammatory therapy assumes greater importance.

In order to minimize the incidence of side effects, it would be appropriate to start therapy with the minimum dose of dexketoprofen necessary to guarantee a prompt remission of the symptoms.

In the event that signs of toxicity or side effects from the use of this drug appear, the patient should immediately contact his doctor and decide if necessary to stop the administration of DESKETO ®

PREGNANCY AND BREASTFEEDING

Known the key role of prostaglandins in supporting cell proliferation and differentiation, necessary to safeguard the correct process of embryonic and fetal development, it is easy to understand the reasons why we do not recommend taking DESKETO ® during pregnancy and in the subsequent period of breastfeeding.

Different studies show in fact how the administration of these drugs, in the above-mentioned periods, can contribute to the onset of malformations and increase the incidence of unwanted abortions.

Interactions

The particular pharmacokinetic and pharmacodynamic characteristics of dexketoprofen, and more generally of non-steroidal anti-inflammatory drugs, expose the patient subjected to DESKETO ® therapy to possible drug interactions.

More precisely, pharmacokinetic studies demonstrate how the contextual intake of

Oral anticoagulants and inhibitors of serotonin reuptake, could increase the risk of bleeding;
Diuretics, ACE inhibitors, angiotensin II antagonists, methotrexate and cyclosporine could exacerbate side effects, especially those at the kidney level;
Non-steroidal anti-inflammatory drugs and corticosteroids could intensify the damaging action of the gastric mucosa;
Antibiotic, i could alter the therapeutic efficacy of both active ingredients;
Sulfonylureas, could determine an altered glycemic control, exerted by the hypoglycemic effect of dexketoprofen.

Contraindications DESKETO ® Dexketoprofen

The use of DESKETO ® is contraindicated in patients who are hypersensitive to the active substance or to one of its excipients, hypersensitive to acetylsalicylic acid and other analgesics, suffering from asthma, nasal polyposis, liver failure, renal to cardiac, intestinal bleeding, ulcerative colitis, Crohn's disease or previous history for the same conditions.

Undesirable effects - Side effects

Although the intake of DESKETO ® is only rarely associated with the appearance of clinically relevant side effects, different clinical trials demonstrate how dexketoprofen can increase the incidence of:

Nausea, abdominal pain, vomiting, diarrhea and dyspepsia and rarely gastritis and peptic ulcers;
Insomnia, headache, drowsiness and dizziness;

Very interesting are also the various data from different epidemiological studies that show how the prolonged intake of non-steroidal anti-inflammatory drugs over time can increase the incidence of renal, liver and cardiovascular diseases.